Historique
Bulletin de Périodique
Addiction , Vol.114, n°1 - January 2019
Paru le :
01/01/2019
Année
2019
Page(s) :
1-200
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
- The CONSORT-SPI 2018 extension: a new guideline for reporting social and psychological intervention trials [Editorial]. Grant S., p. 4-8.
- What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning? [Addiction debate]. Kiluk B.D., Fitzmaurice G.M., Strain E.C., Weiss R.D., p. 9-15.
- Don't ask apple trees to give pears. Nielsen A.S., p. 16-17.
- Double standards and gold standards in the evaluation of how a person feels and functions in substance use disorder pharmacotherapy trials. Witkiewitz K., p. 17-18.
- What defines a clinically meaningful outcome in the treatment of substance use disorders: 'Getting your life back'. Ray L.A., Lim A.C., Shoptaw S., p. 18-20.
- Harm reduction in opioid treatment: an established idea under threat. Kalk N.J., p. 20-21.
- Response to commentaries: The quest(ion) remains in the search for a meaningful reduction-based end-point. Kiluk B.D., Fitzmaurice G.M., Strain E.C., Weiss R.D., p. 21-23.
- Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature. O'Donnell A., Addison M., Spencer L., Zurhold H., Rosenkranz M., McGovern R., et al., p. 24-47.
- Effects of a federal housing voucher experiment on adolescent binge drinking: a secondary analysis of a randomized controlled trial. Osypuk T.L., Joshi S., Schmidt N.M., Glymour M.M., Nelson T.F., p. 48-58.
- Alcohol consumption and all-cause mortality in older adults in Spain: an analysis accounting for the main methodological issues. Ortola R., Garcia-Esquinas E., Lopez-Garcia E., Leon-Munoz L.M., Banegas J.R., Rodriguez-Artalejo F., p. 59-68.
- Profiles of recovery from alcohol use disorder at three years following treatment: can the definition of recovery be extended to include high functioning heavy drinkers? Witkiewitz K., Wilson A.D., Pearson M.R., Montes K.S., Kirouac M., Roos C.R., et al., p. 69-80.
- Parental alcohol use disorder and offspring marital outcomes. Salvatore J.E., Larsson Lonn S., Long E.C., Sundquist J., Kendler K.S., Sundquist K., et al., p. 81-91.
- Naloxone distribution and possession following a large-scale naloxone programme. Madah-Amiri D., Gjersing L., Clausen T., p. 92-100.
- Commentary on Madah-Amiri et al. (2019): Beyond saturation. Bennett A.S., Elliott L., Wolfson-Stofko B., p. 101-102.
- One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Nordt C., Vogel M., Dey M., Moldovanyi A., Beck T., Berthel T., et al., p. 103-111.
- Price elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis. Amlung M., Reed D.D., Morris V., Aston E.R., Metrik J., MacKillop J., p. 112-118.
- Gambling despite financial loss - the role of losses disguised as wins in multi-line slots. Graydon C., Dixon M.J., Stange M., Fugelsang J.A., p. 119-124.
- Commentary on Graydon et al. (2019): Realistic simulations and nudging gambling policy. Murch W.S., Clark L., p. 125-126.
- Longitudinal associations between food insecurity and substance use in a cohort of women with or at risk for HIV in the United States. Whittle H.J., Sheira L.A., Frongillo E.A., Palar K., Cohen J., Merenstein D., et al., p. 127-136.
- Commentary on Whittle et al. (2019): Food insecurity, substance use and women living with/or at risk for HIV-temporal relations and underlying mechanisms. Kalichman S.C., p. 137-138.
- Indexing the 'dark side of addiction': substance-induced affective symptoms and alcohol use disorders. Ehlers C.L., Gilder D.A., Gizer I.R., Wilhelmsen K.C., p. 139-149.
- Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Grebely J., Larney S., Peacock A., Colledge S., Leung J., Hickman M., et al., p. 150-166.
- Commentary on Grebely et al. (2019): Ending HCV epidemics among people who inject drugs. Des Jarlais D.C., p. 167-168.
- A crisis of opioids and the limits of prescription control: United States. Kertesz S.G., Gordon A.J., p. 169-180.
- Commentary on Kertesz & Gordon (2019): Don't abandon opioid prescription control efforts, reform them. Saloner B., p. 181-182.
- Addiction Lives: Betsy Thom. Berridge V., p. 183-185.
- Does the offer of e-cigarettes benefit smoking cessation among unselected smokers? Brown J., Shahab L., West R., p. 186-187.
- Response to Brown et al. 'Does the offer of e-cigarettes benefit smoking cessation among unselected smokers?'. Harhay M.O., Troxel A.B., Volpp K.G., Halpern S.D., p. 187-188.
- Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve. Brewer C., Streel E., p. 188-189.
- Extended-release injectable naltrexone (XR-NTX): a response to clinical issues raised by Brewer & Streel. Jarvis B.P., Holtyn A.F., Subramaniam S., Tompkins D.A., Oga E.A., Bigelow G., et al., p. 189-190.
- The CONSORT-SPI 2018 extension: a new guideline for reporting social and psychological intervention trials [Editorial]. Grant S., p. 4-8.
- What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning? [Addiction debate]. Kiluk B.D., Fitzmaurice G.M., Strain E.C., Weiss R.D., p. 9-15.
- Don't ask apple trees to give pears. Nielsen A.S., p. 16-17.
- Double standards and gold standards in the evaluation of how a person feels and functions in substance use disorder pharmacotherapy trials. Witkiewitz K., p. 17-18.
- What defines a clinically meaningful outcome in the treatment of substance use disorders: 'Getting your life back'. Ray L.A., Lim A.C., Shoptaw S., p. 18-20.
- Harm reduction in opioid treatment: an established idea under threat. Kalk N.J., p. 20-21.
- Response to commentaries: The quest(ion) remains in the search for a meaningful reduction-based end-point. Kiluk B.D., Fitzmaurice G.M., Strain E.C., Weiss R.D., p. 21-23.
- Which individual, social and environmental influences shape key phases in the amphetamine type stimulant use trajectory? A systematic narrative review and thematic synthesis of the qualitative literature. O'Donnell A., Addison M., Spencer L., Zurhold H., Rosenkranz M., McGovern R., et al., p. 24-47.
- Effects of a federal housing voucher experiment on adolescent binge drinking: a secondary analysis of a randomized controlled trial. Osypuk T.L., Joshi S., Schmidt N.M., Glymour M.M., Nelson T.F., p. 48-58.
- Alcohol consumption and all-cause mortality in older adults in Spain: an analysis accounting for the main methodological issues. Ortola R., Garcia-Esquinas E., Lopez-Garcia E., Leon-Munoz L.M., Banegas J.R., Rodriguez-Artalejo F., p. 59-68.
- Profiles of recovery from alcohol use disorder at three years following treatment: can the definition of recovery be extended to include high functioning heavy drinkers? Witkiewitz K., Wilson A.D., Pearson M.R., Montes K.S., Kirouac M., Roos C.R., et al., p. 69-80.
- Parental alcohol use disorder and offspring marital outcomes. Salvatore J.E., Larsson Lonn S., Long E.C., Sundquist J., Kendler K.S., Sundquist K., et al., p. 81-91.
- Naloxone distribution and possession following a large-scale naloxone programme. Madah-Amiri D., Gjersing L., Clausen T., p. 92-100.
- Commentary on Madah-Amiri et al. (2019): Beyond saturation. Bennett A.S., Elliott L., Wolfson-Stofko B., p. 101-102.
- One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Nordt C., Vogel M., Dey M., Moldovanyi A., Beck T., Berthel T., et al., p. 103-111.
- Price elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis. Amlung M., Reed D.D., Morris V., Aston E.R., Metrik J., MacKillop J., p. 112-118.
- Gambling despite financial loss - the role of losses disguised as wins in multi-line slots. Graydon C., Dixon M.J., Stange M., Fugelsang J.A., p. 119-124.
- Commentary on Graydon et al. (2019): Realistic simulations and nudging gambling policy. Murch W.S., Clark L., p. 125-126.
- Longitudinal associations between food insecurity and substance use in a cohort of women with or at risk for HIV in the United States. Whittle H.J., Sheira L.A., Frongillo E.A., Palar K., Cohen J., Merenstein D., et al., p. 127-136.
- Commentary on Whittle et al. (2019): Food insecurity, substance use and women living with/or at risk for HIV-temporal relations and underlying mechanisms. Kalichman S.C., p. 137-138.
- Indexing the 'dark side of addiction': substance-induced affective symptoms and alcohol use disorders. Ehlers C.L., Gilder D.A., Gizer I.R., Wilhelmsen K.C., p. 139-149.
- Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Grebely J., Larney S., Peacock A., Colledge S., Leung J., Hickman M., et al., p. 150-166.
- Commentary on Grebely et al. (2019): Ending HCV epidemics among people who inject drugs. Des Jarlais D.C., p. 167-168.
- A crisis of opioids and the limits of prescription control: United States. Kertesz S.G., Gordon A.J., p. 169-180.
- Commentary on Kertesz & Gordon (2019): Don't abandon opioid prescription control efforts, reform them. Saloner B., p. 181-182.
- Addiction Lives: Betsy Thom. Berridge V., p. 183-185.
- Does the offer of e-cigarettes benefit smoking cessation among unselected smokers? Brown J., Shahab L., West R., p. 186-187.
- Response to Brown et al. 'Does the offer of e-cigarettes benefit smoking cessation among unselected smokers?'. Harhay M.O., Troxel A.B., Volpp K.G., Halpern S.D., p. 187-188.
- Long-acting naltrexone has long-acting benefits and 100% induction rates are not difficult to achieve. Brewer C., Streel E., p. 188-189.
- Extended-release injectable naltrexone (XR-NTX): a response to clinical issues raised by Brewer & Streel. Jarvis B.P., Holtyn A.F., Subramaniam S., Tompkins D.A., Oga E.A., Bigelow G., et al., p. 189-190.
Cote :
Abonnement
Dépouillements
Ajouter le résultat à votre sélection
D. MADAH-AMIRI ;
L. GJERSING ;
T. CLAUSEN
|
2019
Dans Addiction (Vol.114, n°1, January 2019) Article : Périodique
Dans Addiction (Vol.114, n°1, January 2019) Article : Périodique
AIMS: To examine uptake following a large-scale naloxone programme by estimating distribution rates since programme initiation and the proportion among a sample of high-risk individuals who had attended naloxone training, currently possessed or [...]
M. AMLUNG ;
D. D. REED ;
V. MORRIS ;
E. R. ASTON ;
J. METRIK ;
J. MacKILLOP
|
2019
Dans Addiction (Vol.114, n°1, January 2019) Article : Périodique
Dans Addiction (Vol.114, n°1, January 2019) Article : Périodique
BACKGROUND AND AIMS: The evolving legal status of cannabis world-wide necessitates evidence-based regulatory policies to minimize risks associated with cannabis misuse. A prominent concern is the impact legalization may have on the illegal canna[...]
J. GREBELY ;
S. LARNEY ;
A. PEACOCK ;
S. COLLEDGE ;
J. LEUNG ;
M. HICKMAN ;
P. VICKERMAN ;
S. BLACH ;
E. B. CUNNINGHAM ;
K. DUMCHEV ;
M. LYNSKEY ;
J. STONE ;
A. TRICKEY ;
H. RAZAVI ;
R. P. MATTICK ;
M. FARRELL ;
G. J. DORE ;
L. DEGENHARDT
|
2019
Dans Addiction (Vol.114, n°1, January 2019) Article : Périodique
Dans Addiction (Vol.114, n°1, January 2019) Article : Périodique
BACKGROUND AND AIMS: People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with[...]